Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing Blood Loss in Hemipelvectomy Surgery With Tranexamic Acid
NCT03128866Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2017
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tranexamic acid in Pelvic neoplasm (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Total perioperative blood loss at 1 week. Started May 2017; status: active, not recruiting.
02
Drugs
tranexamic acid
03
Conditions
Pelvic neoplasm
Beyond the preview
Go deeper on NCT03128866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128866.